Capoulade R, et al. - In a secondary analysis of the ASTRONOMER (Effects of Rosuvastatin on Aortic Stenosis Progression) trial following up a cohort of 220 patients (60.0% male; mean [SD] age, 58 [13] years) with mild to moderate aortic stenosis, researchers examined the link of baseline plasma levels of lipoprotein(a) (Lp[a]), the content of oxidized phospholipids on apolipoprotein B (OxPL-apoB) and apolipoprotein(a) (OxPL-apo[a]) with the rate of calcific aortic valve stenosis (CAVS) progression. The ASTRONOMER trial was a multicenter investigation performed in 23 Canadian sites to assess the impact of statin therapy (median follow-up, 3.5 years [interquartile range, 2.9-4.5 years]). This analysis included patients with mild to moderate CAVS defined by peak aortic jet velocity ranging from 2.5 to 4.0 m/s, excluding those with peak aortic jet velocity of less than 2.5 m/s or with an indication for statin therapy. Findings revealed a linear association of Lp(a) levels and its content in OxPL with faster CAVS progression.